Search


Current filters:


Start a new search
Add filters:

Use filters to refine the search results.


Results 1-8 of 8 (Search time: 0.007 seconds).
  • previous
  • 1
  • next
Item hits:
PreviewIssue DateTitleAuthor(s)
2003Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemiaHughes, T.; Kaeda, J.; Branford, S.; Rudzki, Z.; Hochhaus, A.; Hensley, M.; Gathmann, I.; Bolton, A.; van Hoomissen, I.; Goldman, J.; Radich, J.
2003Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosisBranford, S.; Rudzki, Z.; Walsh, S.; Parkinson, I.; Grigg, A.; Szer, J.; Taylor, K.; Hermann, R.; Seymour, J.; Arthur, C.; Joske, D.; Lynch, K.; Hughes, T.
2003Successful peripheral blood stem cell mobilisation with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCRHui, C.; Goh, K.; White, D.; Branford, S.; Grigg, A.; Seymour, J.; Kwan, Y.; Walsh, S.; Hoyt, R.; Trickett, A.; Rudzki, Z.; Ma, D.; To, L.; Hughes, T.
2007BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteriaBranford, S.; Seymour, J.; Grigg, A.; Arthur, C.; Rudzki, Z.; Lynch, K.; Hughes, T.
2003Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phaseBranford, S.; Rudzki, Z.; Harper, A.; Grigg, A.; Taylor, K.; Durrant, S.; Arthur, C.; Browett, P.; Schwarer, A.; Ma, D.; Seymour, J.; Bradstock, K.; Joske, D.; Lynch, K.; Gathmann, I.; Hughes, T.
2002Dual transcription of b2a2 and b3a2 BCR-ABL transcripts in chronic myeloid leukaemia is confined to patients with a linked polymorphism within the BCR geneBranford, S.; Hughes, T.; Rudzki, Z.
2002High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistanceBranford, S.; Rudzki, Z.; Walsh, S.; Grigg, A.; Arthur, C.; Taylor, K.; Herrmann, R.; Lynch, K.; Hughes, T.
1999Monitoring chronic myeloid leukaemia therapy by real time quantitative PCR in blood is a reliable alternative to bone marrow cytogeneticsBranford, S.; Hughes, T.; Rudzki, Z.